ArticleClinical pharmacokinetics2021
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Article in Clinical pharmacokinetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03482024 (Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.Diabetes, obesity & metabolism · 2026Article
- GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.Diabetes, obesity & metabolism · 2026Review
- Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.Endocrine · 2026Review
- Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry.International journal of molecular sciences · 2026Review
- Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.Therapeutic advances in endocrinology and metabolism · 2026Review
- Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri-menopausal women.Diabetes, obesity & metabolism · 2025Review
- Intermuscular Adipose Tissue in CKD: A Window into Muscle Quality and Health?Clinical journal of the American Society of Nephrology : CJASN · 2025Review
- Review
- Upcoming drug targets for kidney protective effects in chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment.Diagnostics (Basel, Switzerland) · 2025Review
- The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review.Drug design, development and therapy · 2025Review
- Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.JAMA network open · 2024Article
- Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.Endocrine · 2024Review
- Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study.Endocrinology, diabetes & metabolism · 2024Article
- Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus.World journal of diabetes · 2024Review
- Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.CPT: pharmacometrics & systems pharmacology · 2024Article
- Tirzepatide: A Review in Type 2 Diabetes.Drugs · 2024Review
- Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe pharmacokinetics (PK) and single-dose tolerability of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist being developed for once-weekly treatment of type 2 diabetes (T2D), weight management, and nonalcoholic steatohepatitis, was evaluated in subjects with renal impairment versus healthy subjects with normal renal function.
methodsForty-five subjects, categorized by baseline renal status, i.e. mild (n = 8, estimated glomerular filtration rate [eGFR] 60-89 mL/min/1.73m
resultsTirzepatide exposure was similar across renal impairment groups and healthy subjects. The 90% CI of ratios of AUCs and C
conclusionThere were no clinically relevant effects of renal impairment on tirzepatide PK. Dose adjustment may not be required for patients with renal impairment. CLINICAL
trial registrationClinicalTrials.gov NCT03482024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.